PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin

Frailty Clinical Trial

— PROMETEO  

Official title:

PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04856683
• Other study ID #: PROMETEO
• Status: Recruiting
• Start date: August 10, 2020
• Est. completion date: August 9, 2024

Study information

• Verified date: November 2022
• Source: University of Roma La Sapienza
• Contact: Andrea M Isidori, Prof
• Phone: 0039649972603
• Email: andrea.isidori[@]uniroma1.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multicenter, observational, retrospective and prospective study for the evaluation of precision medicine to target frailty of endocrine-metabolic origin, with a genetic study.

Description:

Overall summary Frailty results from the lifelong accumulation of damage caused by age- and disease-related impairment of the repair network. The amount of cellular damage needed to alter function is uncertain and determined on an individual basis. Assessing cumulative dysfunction in different systems (hormonal, metabolic, immune, cardiovascular, and skeletal) is crucial as the relationship with frailty is nonlinear and not linked to the severity in one system. When subtle, declining functions reaches an aggregate crucial level, and frailty becomes evident. The frail individual is who, after a mild stressor event, undergoes a larger deterioration, which manifest as functional dependency (hospitalization), and who does not return to baseline homoeostasis (favoring polypharmacy). By implementing precision medicine, retrospective and prospective data collected in five referral centers covering densely populated regions in Italy, will be merged and thoroughly analyzed. This network aims at identifying novel biomarkers, predictors of treatment response, and simplified management for complex multiple endocrine comorbidities. The network will investigate emerging and highly prevalent disorders linked to frailty: the gonadal and adrenal, metabolic, neuroendocrine, skeletal. The network will generate scores and precision-medicine based algorithms for the fragile population, often excluded from clinical trials while absorbing most of healthcare expenditure. Background Frailty is raising globally. Patients with multiple endocrine and metabolic comorbidities (MEDs) are at high risk for inappropriate prescriptions, with negative effects on health outcomes and costs. Endocrine and metabolic comorbidities often coexist with frailty being the common endpoint in patients requiring intensive medical care (falls, disability, hospitalization, and mortality). Concomitant multiple medications aggravate frailty by increasing the risk of interactions, adverse effects and reduce efficacy. The cost of supporting these high-risk population are no longer sustainable for the National Health System (NHS). The pathophysiology of frailty is poorly understood, but multiple endocrine dysfunctions are often associated. Dysregulation of the hypothalamic-pituitary-gonadal and adrenal axes are often associated with metabolic disease (Type 2 Diabetes Mellitus-T2D) as well as bone diseases. In 2018 data from the European Male Aging Study (EMAS) showed that both androgen and nonandrogenic anabolic hormones were independently associated with change in frailty status. Other studies showed that frailty was independently associated with chronically raised diurnal cortisol. Diabetes and osteoporosis (OP) are commonly associated with a significant health burden, especially in elderly individuals. Diabetes is also associated with a wide spectrum of comorbidities (cardiovascular disease, impairment of bone quality, hypogonadism, reduced quality of life, obesity). OP is a complex disorder whose pathogenesis is due to the interaction of various predisposing genetic and epigenetic factors regulating bone and mineral metabolism and non-skeletal risk factors that could influence the risk of fall. Genome-wide association studies (GWAS), epigenetic factors and circulating micro-RNA have opened new horizons for the discovery of genetic loci and variants associated with OP and fracture risk, identifying replicated genetic loci associated with OP. Circulating microRNA profiles have also a prognostic value making them attractive, blood-based, non-invasive biomarkers for prediction and staging of endocrine diseases. Moreover, evidence suggests that inflammation has a major role in the pathophysiology of frailty through an abnormal, low-grade inflammatory chronic response that is hyper-responsive to stimuli. Several inflammatory cytokines have been independently associated with frailty and a link was demonstrated between immune cell function and steroid hormone levels in the recently published DREAM trial. Response to therapy in T2D is often patient-related especially in frail patients. However specific biomarkers are needed for disease monitoring and prediction of disease progression or therapy response. Finally, pituitary diseases are associated with increased mortality and morbidity. This can be a direct effect of hormonal hypersecretion but also secondary to hypopituitarism (HP) caused by mass effect, or a direct consequence of trauma, as well as an important side effect of the treatment itself on pituitary lesions (novel immune check-point inhibitors). HP is globally under-diagnosed and insidious with tremendous effects on quality of life (QoL) as well. All the above mentioned and several other studies suggest an important role of the endocrine system on the development of frailty. It is very likely that comorbidities and drugs can accelerate the frailty of endocrine and metabolic origin. Finally, as concern inappropriate prescriptions, some algorithms were demonstrated particularly reliable. Combining clinical, epidemiological, social, hospital admissions and drug prescription data, has been proven a valid approach to identify inappropriate prescriptions due to drug ineffectiveness and to evaluate cost of polypharmacy. Hypothesis and Significance Dysregulation of glucocorticoid secretion and hypogonadism due to primary adrenal or gonadal disorders are independent contributors to frailty and failure to treat effectively cardiovascular, metabolic and bone diseases. Prompt restoration of gonadal and adrenal function, when altered, can reduce the need for multi-drug prescription necessary to target high blood pressure, cardiovascular remodeling, osteoporosis and diabetes mellitus. Less than 50% of patients with T2D had good glycemic control, understanding the mechanisms of Dipeptidyl peptidase-4 (DPP4) inhibitors and Glucagon-like peptide 1 (GLP1)-receptor agonist therapy is needed to predict the response to treatment. Genetic analysis and circulating microRNA profiling may help choosing the appropriate glucose-lowering drugs in T2D patients. The high prevalence of pituitary and neuroendocrine disorders has a significant impact on morbidity, mortality and QoL. Tailoring diagnostic and therapeutic strategies will lead to early diagnosis of these diseases and their complications allowing to select the best long-term management. A correlation between genetic and epigenetic risk of OP and fragility fractures (FF), two major components of frailty, is hypothesized and the investigators aim to identify early the subjects at higher risk and predict their response to anti-fracture drug. Some complex endocrine disorders require extensive use of healthcare resources. Health Care Utilization (HCU) data offer accurate information on the prevalence, incidence, and duration of drugs use providing a comprehensive picture of the therapeutic habits. Linking prescription and clinical-administrative data could allow this network to investigate the inappropriate prescription patterns and the association with worse clinical outcomes. Implications of the Study The case load of hospital care, diagnostic procedures and drug costs for non-communicable diseases is exceeding sustainability in all countries with a negative impact on public health system. The exponential rise in costs is due to the ageing of the population, prevalence of chronic disorders, improved acute care and new expensive drugs. Rationalization of expenditures is mandatory. Personalize diagnostic procedures, therapeutic approaches and management of comorbidities in highly prevalent disorders is only the immediately sustainable approach. The endocrine and metabolic disorders offer the ideal model to quantify the advantages of shifting from a non-personalized approached to precision etiological treatment strategies. This can lead to a rapid and substantial decline in cost expenditure in terms of number of hospital access, prescribed investigations, and inappropriate medication use. Expected outcomes is a reduction of NIH cost due to saving in 1) polypharmacy and 2) reduced hospitalization for the greater efficacy of drugs prescribed using and personalized algorithm, 3) reduced side effects due to multiple-drug interactions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1100
• Est. completion date: August 9, 2024
• Est. primary completion date: August 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• presence of endocrine and metabolic diseases (hypothalamic-pituitary-gonadal and adrenal diseases, type 2 diabetes mellitus, and bone diseases);
• signed informed consent to participate in the study.

Related Conditions & MeSH terms

• Frailty

Locations

Country	Name	City	State
Italy	Azienda Ospedaliero-Universitaria Careggi	Florence
Italy	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Milan
Italy	Azienda Ospedaliero-Universitaria Policlinico Umberto I	Rome
Italy	Ospedale San Giovanni Calibita-Fatebenefratelli Fondazione Fatebenefratelli per la Ricerca e la Formazione Sanitaria e Sociale	Rome
Italy	Azienda Ospedaliero-Universitaria Senese	Siena

Sponsors (1)

Lead Sponsor	Collaborator
University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

References & Publications (55)

Andela CD, Scharloo M, Ramondt S, Tiemensma J, Husson O, Llahana S, Pereira AM, Kaptein AA, Kamminga NG, Biermasz NR. The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary. 2016 Jun;19(3):293-302. doi: 10.1007/s11102-016-0707-4. — View Citation

Andrew T, Antioniades L, Scurrah KJ, Macgregor AJ, Spector TD. Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J Bone Miner Res. 2005 Jan;20(1):67-74. Epub 2004 Oct 25. — View Citation

Arden NK, Baker J, Hogg C, Baan K, Spector TD. The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res. 1996 Apr;11(4):530-4. — View Citation

Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M; Italian Study Group of Acromegaly. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012 Aug;167(2):189-98. Epub 2012 May 17. — View Citation

Carosi G, Malchiodi E, Ferrante E, Sala E, Verrua E, Profka E, Giavoli C, Filopanti M, Beck-Peccoz P, Spada A, Mantovani G. Hypothalamic-Pituitary Axis in Non-Functioning Pituitary Adenomas: Focus on the Prevalence of Isolated Central Hypoadrenalism. Neuroendocrinology. 2015;102(4):267-273. Epub 2015 Apr 29. — View Citation

Catanzaro G, Besharat ZM, Chiacchiarini M, Abballe L, Sabato C, Vacca A, Borgiani P, Dotta F, Tesauro M, Po A, Ferretti E. Circulating MicroRNAs in Elderly Type 2 Diabetic Patients. Int J Endocrinol. 2018 Apr 10;2018:6872635. doi: 10.1155/2018/6872635. eCollection 2018. — View Citation

Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V, Di Lembo S, Epaminonda P, Masserini B, Beck-Peccoz P, Orsi E, Ambrosi B, Arosio M. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care. 2007 Jan;30(1):83-8. — View Citation

Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, Santini SA, Guglielmi G, Carnevale V, Scillitani A. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007 Oct 16;147(8):541-8. — View Citation

Chiodini I, Torlontano M, Scillitani A, Arosio M, Bacci S, Di Lembo S, Epaminonda P, Augello G, Enrini R, Ambrosi B, Adda G, Trischitta V. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol. 2005 Dec;153(6):837-44. — View Citation

Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011 Mar;96(3):632-42. doi: 10.1210/jc.2010-1942. Epub 2010 Dec 30. Review. — View Citation

Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013 Mar 2;381(9868):752-62. doi: 10.1016/S0140-6736(12)62167-9. Epub 2013 Feb 8. Review. Erratum in: Lancet. 2013 Oct 19;382(9901):1328. — View Citation

Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004 Feb;25(1):102-52. Review. — View Citation

Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013 Apr;98(4):1361-75. doi: 10.1210/jc.2012-4075. Epub 2013 Mar 7. Review. — View Citation

DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):787-835, ix. Review. — View Citation

Dujic T, Zhou K, Tavendale R, Palmer CN, Pearson ER. Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. Diabetes Care. 2016 Nov;39(11):1896-1901. Epub 2016 Aug 4. — View Citation

Eisman JA. Genetics of osteoporosis. Endocr Rev. 1999 Dec;20(6):788-804. Review. — View Citation

Finkelstein J, Friedman C, Hripcsak G, Cabrera M. Potential utility of precision medicine for older adults with polypharmacy: a case series study. Pharmgenomics Pers Med. 2016 Apr 15;9:31-45. doi: 10.2147/PGPM.S101474. eCollection 2016. — View Citation

Giavoli C, Profka E, Verrua E, Ronchi CL, Ferrante E, Bergamaschi S, Sala E, Malchiodi E, Lania AG, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. J Clin Endocrinol Metab. 2012 Nov;97(11):3983-8. doi: 10.1210/jc.2012-2477. Epub 2012 Aug 17. — View Citation

Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JO. Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012 Apr;23(3):278-82. doi: 10.1016/j.ejim.2011.10.013. Epub 2011 Nov 15. Review. — View Citation

Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. 2013 Sep;9(9):513-21. doi: 10.1038/nrendo.2013.86. Epub 2013 Apr 30. Review. — View Citation

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602. — View Citation

Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, Langdahl B, van Meurs JB, Mosekilde L, Scollen S, Albagha OM, Bustamante M, Carey AH, Dunning AM, Enjuanes A, van Leeuwen JP, Mavilia C, Masi L, McGuigan FE, Nogues X, Pols HA, Reid DM, Schuit SC, Sherlock RE, Uitterlinden AG; GENOMOS Study. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA. 2004 Nov 3;292(17):2105-14. — View Citation

Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):173-185. doi: 10.1016/S2213-8587(17)30398-4. Epub 2017 Dec 8. — View Citation

Jamaluddin JL, Huri HZ, Vethakkan SR. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 2016 Jun;17(8):867-81. doi: 10.2217/pgs-2016-0010. Epub 2016 Jun 1. — View Citation

Johar H, Emeny RT, Bidlingmaier M, Reincke M, Thorand B, Peters A, Heier M, Ladwig KH. Blunted diurnal cortisol pattern is associated with frailty: a cross-sectional study of 745 participants aged 65 to 90 years. J Clin Endocrinol Metab. 2014 Mar;99(3):E464-8. doi: 10.1210/jc.2013-3079. Epub 2014 Feb 24. — View Citation

Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003 Sep;6(2):81-7. — View Citation

Joseph SM, Rich MW. Targeting Frailty in Heart Failure. Curr Treat Options Cardiovasc Med. 2017 Apr;19(4):31. doi: 10.1007/s11936-017-0527-5. Review. — View Citation

Kane AE, Gregson E, Theou O, Rockwood K, Howlett SE. The association between frailty, the metabolic syndrome, and mortality over the lifespan. Geroscience. 2017 Apr;39(2):221-229. doi: 10.1007/s11357-017-9967-9. Epub 2017 Mar 9. — View Citation

Ladapo JA, Budoff MJ, Sharp D, Kuo JZ, Huang L, Maniet B, Herman L, Monane M. Utility of a Precision Medicine Test in Elderly Adults with Symptoms Suggestive of Coronary Artery Disease. J Am Geriatr Soc. 2018 Feb;66(2):309-315. doi: 10.1111/jgs.15215. Epub 2017 Dec 6. — View Citation

Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, Scollen S, Lips P, Lorenc R, Obermayer-Pietsch B, Reid DM, Armas JB, Arp PP, Bassiti A, Bustamante M, Husted LB, Carey AH, Pérez Cano R, Dobnig H, Dunning AM, Fahrleitner-Pammer A, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, Masi L, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, Mosekilde L, Nogués X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Ioannidis JP; APOSS investigators; DOPS investigators; EPOS investigators; EPOLOS investigators; FAMOS investigators; LASA investigators; ERGO investigators; GENOMOS Study. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone. 2008 May;42(5):969-81. doi: 10.1016/j.bone.2007.11.007. Epub 2007 Dec 3. — View Citation

Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004 Dec;61(6):768-77. — View Citation

Mazziotti G, Chiavistelli S, Giustina A. Pituitary diseases and bone. Endocrinol Metab Clin North Am. 2015 Mar;44(1):171-80. doi: 10.1016/j.ecl.2014.10.014. Epub 2014 Nov 4. Review. — View Citation

Mazziotti G, Doga M, Frara S, Maffezzoni F, Porcelli T, Cerri L, Maroldi R, Giustina A. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine. 2016 Apr;52(1):103-10. doi: 10.1007/s12020-015-0738-z. Epub 2015 Oct 3. — View Citation

Mazziotti G, Frara S, Giustina A. Pituitary Diseases and Bone. Endocr Rev. 2018 Aug 1;39(4):440-488. doi: 10.1210/er.2018-00005. Review. — View Citation

Morley JE. Hormones and Sarcopenia. Curr Pharm Des. 2017 Nov 28;23(30):4484-4492. doi: 10.2174/1381612823666161123150032. Review. — View Citation

Ralston SH, Uitterlinden AG, Brandi ML, Balcells S, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Scollen S, Bustamante M, Husted LB, Carey AH, Diez-Perez A, Dunning AM, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, del Monte F, Pols HA, Reeve J, Reid DM, Renner W, Rivadeneira F, van Schoor NM, Sherlock RE, Ioannidis JP; GENOMOS Investigators. Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Med. 2006 Apr;3(4):e90. Epub 2006 Feb 21. Erratum in: PLoS Med. 2006 May;3(5):e90. — View Citation

Ralston SH. Genetic determinants of susceptibility to osteoporosis. Curr Opin Pharmacol. 2003 Jun;3(3):286-90. Review. — View Citation

Ramaswami R, Bayer R, Galea S. Precision Medicine from a Public Health Perspective. Annu Rev Public Health. 2018 Apr 1;39:153-168. doi: 10.1146/annurev-publhealth-040617-014158. Epub 2017 Nov 20. Review. — View Citation

Richards JB, Zheng HF, Spector TD. Genetics of osteoporosis from genome-wide association studies: advances and challenges. Nat Rev Genet. 2012 Jul 18;13(8):576-88. doi: 10.1038/nrg3228. Review. — View Citation

Rocha-Braz MG, Ferraz-de-Souza B. Genetics of osteoporosis: searching for candidate genes for bone fragility. Arch Endocrinol Metab. 2016 Aug;60(4):391-401. doi: 10.1590/2359-3997000000178. Review. — View Citation

Ronchi CL, Giavoli C, Ferrante E, Verrua E, Bergamaschi S, Ferrari DI, Corbetta S, Montefusco L, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P. Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. Eur J Endocrinol. 2009 Jul;161(1):37-42. doi: 10.1530/EJE-09-0222. Epub 2009 Apr 7. — View Citation

Rossi MC, Nicolucci A, Arcangeli A, Cimino A, De Bigontina G, Giorda C, Meloncelli I, Pellegrini F, Valentini U, Vespasiani G; Associazione Medici Diabetologi Annals Study Group. Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics. Diabetes Care. 2008 Nov;31(11):2166-8. doi: 10.2337/dc08-0469. Epub 2008 Aug 11. — View Citation

Saad F, Röhrig G, von Haehling S, Traish A. Testosterone Deficiency and Testosterone Treatment in Older Men. Gerontology. 2017;63(2):144-156. doi: 10.1159/000452499. Epub 2016 Nov 18. Review. — View Citation

Sebastiani G, Nigi L, Grieco GE, Mancarella F, Ventriglia G, Dotta F. Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging? J Endocrinol Invest. 2017 Jun;40(6):591-610. doi: 10.1007/s40618-017-0611-4. Epub 2017 Feb 17. Review. — View Citation

Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM. Mortality in patients with pituitary disease. Endocr Rev. 2010 Jun;31(3):301-42. doi: 10.1210/er.2009-0033. Epub 2010 Jan 19. Review. — View Citation

Sonino N, Fava GA. Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15(5):361-73. Review. — View Citation

Swiecicka A, Eendebak RJAH, Lunt M, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Slowikowska-Hilczer J, Lean MEJ, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FCW, Rutter MK; European Male Ageing Study Group. Reproductive Hormone Levels Predict Changes in Frailty Status in Community-Dwelling Older Men: European Male Ageing Study Prospective Data. J Clin Endocrinol Metab. 2018 Feb 1;103(2):701-709. doi: 10.1210/jc.2017-01172. — View Citation

Tanriverdi F, Schneider HJ, Aimaretti G, Masel BE, Casanueva FF, Kelestimur F. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev. 2015 Jun;36(3):305-42. doi: 10.1210/er.2014-1065. Epub 2015 May 7. Review. — View Citation

Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavo S, Ferone D, Montini M, Bondanelli M, De Menis E, Martini C, Puxeddu E, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Peraga G, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Berton A, Serban AL, Baldelli R, Fatti LM, Colao A, Arosio M; Italian Study Group of Acromegaly. Acromegaly is associated with increased cancer risk: a survey in Italy. Endocr Relat Cancer. 2017 Sep;24(9):495-504. doi: 10.1530/ERC-16-0553. Epub 2017 Jul 14. — View Citation

Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001 Feb 10;357(9254):425-31. — View Citation

Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Reeve J, Reid DM, Amedei A, Bassiti A, Bustamante M, Husted LB, Diez-Perez A, Dobnig H, Dunning AM, Enjuanes A, Fahrleitner-Pammer A, Fang Y, Karczmarewicz E, Kruk M, van Leeuwen JP, Mavilia C, van Meurs JB, Mangion J, McGuigan FE, Pols HA, Renner W, Rivadeneira F, van Schoor NM, Scollen S, Sherlock RE, Ioannidis JP; APOSS Investigators; EPOS Investigators; EPOLOS Investigators; FAMOS Investigators; LASA Investigators; Rotterdam Study Investigators; GENOMOS Study. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med. 2006 Aug 15;145(4):255-64. Erratum in: Ann Intern Med. 2006 Dec 19;145(12):936. Amidei, Antonietta [corrected to Amedei, Antonietta]. — View Citation

van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW, Romijn JA. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab. 2005 Jun;90(6):3279-86. Epub 2005 Mar 1. — View Citation

van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O, Lorenc R, Obermayer-Pietsch B, Ohlsson C, Pettersson U, Reid DM, Rousseau F, Scollen S, Van Hul W, Agueda L, Akesson K, Benevolenskaya LI, Ferrari SL, Hallmans G, Hofman A, Husted LB, Kruk M, Kaptoge S, Karasik D, Karlsson MK, Lorentzon M, Masi L, McGuigan FE, Mellström D, Mosekilde L, Nogues X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Weber K, Ioannidis JP, Uitterlinden AG; GENOMOS Study. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008 Mar 19;299(11):1277-90. doi: 10.1001/jama.299.11.1277. — View Citation

Webb SM, Crespo I, Santos A, Resmini E, Aulinas A, Valassi E. MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease. Eur J Endocrinol. 2017 Jul;177(1):R13-R26. doi: 10.1530/EJE-17-0041. Epub 2017 Mar 28. Review. — View Citation

Zhukouskaya VV, Eller-Vainicher C, Gaudio A, Cairoli E, Ulivieri FM, Palmieri S, Morelli V, Orsi E, Masserini B, Barbieri AM, Polledri E, Fustinoni S, Spada A, Fiore CE, Chiodini I. In postmenopausal female subjects with type 2 diabetes mellitus, vertebral fractures are independently associated with cortisol secretion and sensitivity. J Clin Endocrinol Metab. 2015 Apr;100(4):1417-25. doi: 10.1210/jc.2014-4177. Epub 2015 Jan 15. — View Citation

* Note: There are 55 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite Clinical Score	To derive a Composite Clinical Score able to identify endocrine fragile patients (occurrence of at least one of the following events: falls, disability, hospitalization, and mortality within the previous 18-months).	Baseline
Primary	Prediction of frailty	Validation of Composite Clinical Score to predict frailty occurrence	Baseline
Secondary	Peripheral blood mononuclear cell subpopulations	Number of cells (number per mm3) of peripheral blood mononuclear cell subpopulations	Baseline
Secondary	Molecular profiling	Circulating miRNA in blood samples from patients with adrenal and gonadal diseases	Baseline
Secondary	Steroid profiling	Steroid metabolites assessed by liquid chromatography-mass spectrometry (LC-MS/MS)	Baseline
Secondary	Measure of vascular flows though contrast enhanced ultrasound in endocrine glands	Coupling vascular glandular inflow with hormonal outflow	Baseline
Secondary	Measure of liver vascular inflow through 4 dimensional (4D)-flow MRI	Coupling liver vascular inflow with liver glucocorticoid metabolism	Baseline
Secondary	Serotonin Transporter 5-HTTLPR polymorphism	To study the effects of Serotonin Transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin in a population of T2D subjects and its relationship with glycometabolic control	Baseline
Secondary	Circulating microRNAs	To evaluate circulating microRNAs in blood samples from patients with T2D before and after GLP1-receptor agonist or DPP4 inhibitors therapy, in order to identify markers predicting treatment response, therapeutic efficacy and side effects	Baseline and post 6 months
Secondary	Gene polymorphisms	To evaluate gene polymorphisms in blood samples from patients with T2D before and after GLP1-RA or DPP4 inhibitors therapy, in order to identify markers predicting treatment response, therapeutic efficacy and side effects	Baseline and post 6 months
Secondary	Cardio-metabolic stratification risk	To elaborate a risk stratification approach for cardiovascular, metabolic and cerebrovascular outcomes in pituitary patients aimed to personalize treatment and follow-up in pituitary diseases.	Baseline
Secondary	Psychological function	Psychological function assessed by QoL questionnaire in pituitary diseases	Baseline
Secondary	Osteoporosis stratification risk	Gene analysis to elaborate a risk screening panel for osteoporosis	Baseline
Secondary	Epigenetic biomarkers	To individuate possible serum epigenetic biomarkers of osteoporosis status and fragility fractures risk	Baseline
Secondary	Multiple endocrine and metabolic comorbidities	To identify patients with multiple endocrine and metabolic comorbidities and assess the incidence of major clinical events using regional registries	Baseline
Secondary	Inappropriate therapeutic regimen	To individuate inappropriate therapeutic regimen (drug prescriptions or suboptimal adherence) in patients with multiple endocrine and metabolic comorbidities	Baseline